Is it the right call for Eli Lilly to stop disclosing its Phase 1 pipeline? Analysts and former Lilly execs weigh in.
Eli Lilly's headquarters in Indianapolis (Scott Olson/Getty Images)
August 27, 2026 11:02 AM EDTUpdated 11:14 AM
R&DPharma
Lilly's move to hide Phase 1 pipeline draws mixed reviews
Kyle LaHucik
Eli Lilly has stopped disclosing its early-stage pipeline and most deal values as it grows larger. An analysis of why the…
Eli Lilly made 11 biotech acquisitions in H1 2026, dominating the industry's M&A total while targeting vaccines, CAR-T, ADCs &…
Lilly's Carole Ho talks blood tests for early Alzheimer's detection, the $2.8B AtaiBeckley psychedelics deal and Lilly's broader…
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
In this week’s edition of InnovationRx, we look at Lilly’s 2Q earnings, a cannabis-derived drug for PTSD, Apnimed’s IPO and more
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere,…
